Molly McElwee-Malloy, Harsimran Singh, Haidee Sanchez, Michelle Manning, Steph Habif
To assess satisfaction and trust related to different insulin delivery devices (IDD) in people with type 1 diabetes (T1D) before and after starting Basal-IQ® technology on the t:slim X2™ insulin pump.
Participants completed an online baseline survey including questions about their IDD (prior to Basal-IQ technology). This survey was repeated after 6 months (Post-Assessment) to assess participants’ experience with Basal-IQ technology. Participants elaborated on their experiences with their IDD in open-ended items on satisfaction and trust with their devices.
Overall, there was a significant increase in both satisfaction and trust related to insulin delivery device after 6 months of Basal‑IQ technology use (p<0.001). Although a significant increase in IDD satisfaction was seen across participants (irrespective of Previous IDD type) at Post- Assessment, those on multiple daily injections (MDI) reported the largest increase in satisfaction (4.8 to 9.2, 91% increase), followed by previous Medtronic users (6.3 to 8.6, 36% increase). Previous MDI, OmniPod, and Medtronic users all showed a significant increase in IDD trust at Post-Assessment.
This study demonstrated notable improvements in IDD-related satisfaction and trust after 6 months of Basal-IQ technology use.
Consult user guides for our pumps, infusion sets, predictive technology, and reporting app.
View DocumentationUse our education tutorials to train your patients or CDEs on our easy-to-use products.
View ResourcesPrescribing is easy with our customized referral process and insurance benefits check.
Learn MoreReferences:
1. Forlenza GP, et al. Diabetes Care. 2018;41(10):2155-2161.
2. Editorial. Lancet Diabetes Endocrinol.
2019;7(9):657.
3. Subramanian S, et al. Diabetes Spectr. 2014;27(2):87-91.
4. Fleming GA, et al. Diabetes Care.
2020;43(1):250-260.
5. Tanenbaum ML, et al. J Diabetes Sci Technol. 2017;11(3):484-492.
6. Arafat Y, et al. The Use of
Measurements ... Present Challenges and Future Solutions [Internet]. 2018
7. Liberman A, et al. Diabetes Technol
Ther. 2016;18(Suppl 1):S101-S11.
Important Safety Information
Caution: Federal (USA) law restricts the t:slim X2 insulin pump and the t:slim X2 insulin pump with Basal-IQ technology to sale by or on the order of a physician. The t:slim X2 insulin pump with Basal-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Basal-IQ technology, and a compatible integrated continuous glucose monitor (iCGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the t:slim X2 insulin pump with Basal-IQ technology can be used to suspend insulin delivery based on CGM sensor readings. The pump and the System are indicated for use in individuals 6 years of age and greater. The pump and the System are intended for single patient use. The pump and the System are indicated for use with NovoLog or Humalog U-100 insulin. The System is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts. The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. For additional important safety information, visit www.tandemdiabetes.com/safetyinfo.